我如何管理骨髓瘤药物的毒性
本文以5个病例短文讨论如何预防和管理含蛋白酶体抑制剂、免疫调节药物和单克隆抗体的抗骨髓瘤方案最常见的非血液学不良事件,强调在诊断和复发时需为每位患者权衡疗效与毒性,避免因药物相关不良事件而过早或不必要地减量或停药。
要点
- 抗骨髓瘤方案日益复杂且疗程延长,需警惕早期和晚期不良反应。
- 真实世界患者可能更虚弱或合并症更多,治疗决策需个体化权衡疗效与毒性。
- 因药物相关不良事件过早或不必要减量或停药可能降低生活质量并负面影响结局。
核心结论
- 准确识别和管理当前治疗方案潜在不良反应是骨髓瘤诊疗的基石。
- 治疗决策过程需为每位患者仔细权衡疗效与毒性特征。
- 因药物相关不良事件过早和/或不必要减量或停药可能不仅降低生活质量,还负面影响患者结局。
研究设计与样本
- 本文为综述,采用5个病例短文讨论如何预防和管理抗骨髓瘤治疗方案的常见非血液学不良事件。
主要发现
- 临床试验主张采用含新型抗骨髓瘤药物类别组合的长期而非短期治疗方案。
- 推荐方案的总体毒性特征可被认为良好,但其复杂性增加和长期使用要求对早期和晚期副作用保持高度警惕。
临床怎么用
- 骨髓瘤医生在诊断和复发时需为每位患者仔细权衡疗效与毒性特征。
- 需准确识别和管理含蛋白酶体抑制剂、免疫调节药物和单克隆抗体的方案最常见的非血液学不良事件。
- 应避免因药物相关不良事件过早和/或不必要地减量或停药以避免负面影响结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The treatment of multiple myeloma is considered a continuously evolving paradigm as a result of the growing availability of new and highly effective drugs, including first- and second-generation proteasome inhibitors, immunomodulatory agents, and monoclonal antibodies. Clinical trials advocate long-term rather than short-term treatment schedules with combinations of these new anti-myeloma drug classes. Although the overall toxicity profile of the recommended regimens can be considered favorable, their increasing complexity and prolonged use warrant a heightened vigilance for early and late side effects, a priori because real-life patients can be more frail or present with 1 or more comorbidities. The treatment decision process, at diagnosis and at relapse, therefore requires myeloma physicians to carefully balance efficacy and toxicity profiles for each individual patient. Early and/or unnecessary tapering or treatment discontinuation for drug-related adverse events may not only reduce patients' quality of life, but also negatively impact their outcome. Accurate knowledge in recognizing and managing the potential side effects of present-day treatment regimens is therefore a cornerstone in myeloma care. Using 5 case vignettes, we discuss how to prevent and manage the most common nonhematological adverse events of anti-myeloma treatment regimens containing proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies.
引用
- Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017. PMID: 28275090. doi:10.1182/blood-2017-01-725705
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。